Scarica l'app Stockscreener
14.22
4.56%
0.513
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution - Pharmacy Practice News
Why Amneal (AMRX) stock is trading up today - MSN
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data - Sahm
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations - Yahoo Finance
Amneal reports interim data on Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa
Amneal reports interim data for Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution - The Globe and Mail
Amneal reports interim data on Parkinson’s drug CREXONT - Investing.com UK
Amneal Pharmaceuticals Reports Positive Interim Data from Phase 4 ELEVATE-PD Study Demonstrating Benefits of CREXONT in Parkinson's Disease Patients - Quiver Quantitative
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease - The Manila Times
Parkinson’s study: CREXONT adds over 3 hours of daily 'Good On' time - Stock Titan
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
AMRX News | AMNEAL PHARMACEUTICALS INC (NASDAQ:AMRX) - ChartMill
Amneal Stock Up on FDA Approval of Romidepsin Injection for Lymphoma PatientsNews and Statistics - IndexBox
Why Amneal (AMRX) Stock Is Trading Up Today - Yahoo Finance UK
Amneal Pharmaceuticals Inc (AMRX) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution - Proactive financial news
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
Amneal Pharmaceuticals Advances After Securing FDA Clearance for Cancer Treatment (AMRX) - Yahoo Finance
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug - Investing.com
FDA approves ready-to-use lymphoma drug, Amneal gains 180 days of exclusivity - Stock Titan
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? - Yahoo! Finance Canada
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Amneal CEO to present at Goldman Sachs 2026 Global Healthcare Conference in June - Pluang
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains - Sahm
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now? - The Globe and Mail
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - MSN
Is Amneal Pharmaceuticals (AMRX) Poised for Growth After a Strong Q1 2026 - Kavout
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- G - GuruFocus
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- GF Value $7.57 vs Price $12.21 - GuruFocus
Stronger Q1 Profitability And Reaffirmed Outlook Could Be A Game Changer For Amneal (AMRX) - simplywall.st
Amneal Pharmaceuticals Is Maintained at Overweight by Barclays - Moomoo
0.19%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):